Management of Bleeding in ITP Patients

Primary Treatment Approach

The American Society of Hematology recommends IVIg as the primary treatment for bleeding in ITP patients, with a rapid onset of action (grade 2B evidence), and should be administered immediately along with high-dose corticosteroids to achieve hemostasis by increasing platelet production and reducing platelet destruction 1, 2, 3, 4.
Platelet transfusions should be given in life-threatening bleeding, ranging from every 30 minutes to 8 hours, ideally in conjunction with continuous IVIg infusion to prevent immediate antibody-mediated destruction of transfused platelets 1, 2, 3.

The American Society of Hematology states that antifibrinolytic agents, including tranexamic acid, may be considered as adjunctive therapy for bleeding in thrombocytopenic patients, but their efficacy is unproven 1, 2, 3, 4.
Standard dosing of tranexamic acid would be 1g IV over 10 minutes, based on extrapolation from trauma and surgical bleeding guidelines, though this specific dosing has not been validated in ITP 5.

The 3-hour window for TXA efficacy established in trauma does not apply to ITP, as ITP bleeding is not trauma-related and the pathophysiology is fundamentally different 5, 6.
Do not delay or substitute TXA for proven ITP therapies (IVIg, corticosteroids, platelet transfusion) in life-threatening bleeding scenarios 1, 2, 3, 4.

Immediately administer IVIg (grade 2B) + high-dose corticosteroids (grade 2B) as first-line therapy for life-threatening bleeding in ITP patients 1, 2, 3, 4.
Begin platelet transfusions (every 30 minutes to 8 hours as needed) in conjunction with continuous IVIg infusion 1, 2, 3.
Consider recombinant factor VIIa for refractory life-threatening bleeding, though thrombosis risk exists 1, 2, 3.
Emergent splenectomy should be regarded as heroic and reserved for truly life-threatening bleeding unresponsive to all other measures 1, 2, 3, 4.

No increased thrombotic risk has been demonstrated with TXA in general populations, though ITP patients may have concurrent thrombotic risk factors 5.
Renal function must be assessed, as TXA is renally excreted and requires dose adjustment in renal impairment 5.
Higher doses (≥4g/24h) of TXA are associated with increased seizure risk and should be avoided 5.